Neil T. Conlon

Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Integrating Lifestyle, Mechanistic Therapeutics, and Computational Approaches in Cancer: Highlights from the Irish Association for Cancer Research Annual Conference 2025.

Integrating Lifestyle, Mechanistic Therapeutics, and Computational Approaches in Cancer: Highlights from the Irish Association for Cancer Research Annual Conference 2025.

Journal: Cancers

Published: May 13, 2026

A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients.

A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients.

Journal: The journal of liquid biopsy

Published: April 09, 2026

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.

Journal: Translational oncology

Published: February 19, 2024

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Journal: Molecular cancer

Published: November 02, 2023

Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors.

Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors.

Journal: Life (Basel, Switzerland)

Published: December 09, 2022

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

Journal: PloS one

Published: July 26, 2022

FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.

FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.

Journal: The AAPS journal

Published: June 16, 2022

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.

Journal: International journal of molecular sciences

Published: March 17, 2021

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Journal: Cancers

Published: December 31, 2020

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Journal: British journal of cancer

Published: August 07, 2020

Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.

Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.

Journal: International journal of molecular sciences

Published: December 13, 2019

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Journal: Cancers

Published: March 29, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026